Proxalutamide reduces COVID-19 mortality risk by 92 percent
In a Phase III trial, Proxalutamide reduced mortality and expedited…
In a Phase III trial, Proxalutamide reduced mortality and expedited recovery of hospitalised COVID-19 patients in Brazil.